Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compugen has reported positive in-vivo results for two novel peptide agonists of the MAS G-protein coupled receptor or GPCR, indicating cardio-protective effects and therapeutic potential for the treatment of various cardiovascular and other pathologies.
Subscribe to our email newsletter
The two peptides, CGEN-856 and CGEN-857 were identified using the company’s previously announced GPCR ligand discovery platform.
In an in-vivo model of cardiac remodeling, CGEN-856 and CGEN-857 were shown to afford significant cardio protection, as manifested by reduction of both fibrosis and hypertrophy of cardiomyocytes. Moreover, picomolar concentrations of the peptides had an anti-arrhythmogenic effect in isolated rat hearts following ischemia-reperfusion, as demonstrated by a reduction in the incidence and duration of reperfusion arrhythmias.